News

The Myasthenia Gravis Foundation of America brought together a group of experts with the aim of establishing a formal consensus statement for the treatment and care of patients with myasthenia gravis (MG). An overview on the proposed guidelines was recently published in the article, “Developing treatment…

Biological agents that target inflammation-generating immune cells and signaling molecules could be used to treat myasthenia gravis, French researchers report. Biologics have helped people with other autoimmune diseases, so they might be able to restore balance to MG patients’ immune system, the team said. MG stems from an imbalance between…

Japanese researchers wrote about a myasthenia gravis (MG) patient who showed long-term improvement in disease symptoms after he was treated with blood purification therapy. The case report, “A Case of Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated With Outpatient Periodic Weekly Blood Purification Therapy,” appeared in Internal Medicine, the journal…

Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated with myasthenia gravis (MG), including gastrointestinal side effects of pyridostigmine, the investigational therapy’s developer, GT Biopharma, announced. Preliminary results suggest that GTP-004 enables the safe and well-tolerated administration of…

Women with a rare form of myasthenia gravis (MG) called muscle specific kinase (MuSK) MG can have healthy pregnancies without jeopardizing outcomes or increasing the risk of disease worsening, a small group study suggests. The study, “MuSK Myasthenia gravis and Pregnancy,” was published in the journal Neuromuscular Disorders.